| Cell line name | OPM-2/BR |
|---|---|
| Synonyms | OPM2/BR |
| Accession | CVCL_VJ35 |
| Resource Identification Initiative | To cite this cell line use: OPM-2/BR (RRID:CVCL_VJ35) |
| Comments | Characteristics: Produces Ig lambda. Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade). Derived from sampling site: Peripheral blood. |
| Sequence variations | Heterozygous for CDKN2A p.His83Tyr (c.247C>T) (from parent cell line).Heterozygous for FGFR3 p.Lys650Glu (c.1948A>G) (from parent cell line).Heterozygous for SMAD2 p.Leu87Arg (c.260T>G) (from parent cell line).Homozygous for TP53 p.Arg175His (c.524G>A) (from parent cell line). |
| Disease | Plasma cell myeloma (NCIt: C3242) Multiple myeloma (ORDO: Orphanet_29073) |
| Species of origin | Homo sapiens (Human)
(NCBI Taxonomy: 9606)
|
| Hierarchy | Parent: CVCL_1625 (OPM-2) |
| Sex of cell | Female |
| Age at sampling | 56Y |
| Category | Cancer cell line |
| Publications | PubMed=25382610; DOI=10.1038/bcj.2014.74 |
| Entry history | |
| Entry creation | 07-Sep-2018 |
| Last entry updated | 12-Mar-2020 |
| Version number | 3 |